Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma

KEY CLINICAL MESSAGE: Sorafenib is the standard treatment of hepatocellular carcinoma (HCC). However, fibrolamellar HCC was not included in sorafenib trials. The case is a 26-year-old man with fibrolamellar HCC, who had a cerebrovascular accident (CVA) while being treated with sorafenib. This illust...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandewynckel, Yves-Paul, Geerts, Anja, Verhelst, Xavier, Van Vlierberghe, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184762/
https://www.ncbi.nlm.nih.gov/pubmed/25356226
http://dx.doi.org/10.1002/ccr3.34
_version_ 1782337909320318976
author Vandewynckel, Yves-Paul
Geerts, Anja
Verhelst, Xavier
Van Vlierberghe, Hans
author_facet Vandewynckel, Yves-Paul
Geerts, Anja
Verhelst, Xavier
Van Vlierberghe, Hans
author_sort Vandewynckel, Yves-Paul
collection PubMed
description KEY CLINICAL MESSAGE: Sorafenib is the standard treatment of hepatocellular carcinoma (HCC). However, fibrolamellar HCC was not included in sorafenib trials. The case is a 26-year-old man with fibrolamellar HCC, who had a cerebrovascular accident (CVA) while being treated with sorafenib. This illustrates a probable relationship between use of sorafenib and CVA in low cardiovascular risk patients.
format Online
Article
Text
id pubmed-4184762
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-41847622014-10-29 Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma Vandewynckel, Yves-Paul Geerts, Anja Verhelst, Xavier Van Vlierberghe, Hans Clin Case Rep Case Reports KEY CLINICAL MESSAGE: Sorafenib is the standard treatment of hepatocellular carcinoma (HCC). However, fibrolamellar HCC was not included in sorafenib trials. The case is a 26-year-old man with fibrolamellar HCC, who had a cerebrovascular accident (CVA) while being treated with sorafenib. This illustrates a probable relationship between use of sorafenib and CVA in low cardiovascular risk patients. Blackwell Publishing Ltd 2014-02 2013-12-31 /pmc/articles/PMC4184762/ /pubmed/25356226 http://dx.doi.org/10.1002/ccr3.34 Text en © 2013 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Vandewynckel, Yves-Paul
Geerts, Anja
Verhelst, Xavier
Van Vlierberghe, Hans
Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma
title Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma
title_full Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma
title_fullStr Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma
title_full_unstemmed Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma
title_short Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma
title_sort cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184762/
https://www.ncbi.nlm.nih.gov/pubmed/25356226
http://dx.doi.org/10.1002/ccr3.34
work_keys_str_mv AT vandewynckelyvespaul cerebellarstrokeinalowcardiovascularriskpatientassociatedwithsorafenibtreatmentforfibrolamellarhepatocellularcarcinoma
AT geertsanja cerebellarstrokeinalowcardiovascularriskpatientassociatedwithsorafenibtreatmentforfibrolamellarhepatocellularcarcinoma
AT verhelstxavier cerebellarstrokeinalowcardiovascularriskpatientassociatedwithsorafenibtreatmentforfibrolamellarhepatocellularcarcinoma
AT vanvlierberghehans cerebellarstrokeinalowcardiovascularriskpatientassociatedwithsorafenibtreatmentforfibrolamellarhepatocellularcarcinoma

Ejemplares similares